Condition
HER2 Expression
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Unknown2
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07436858Phase 1Not Yet Recruiting
Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer
NCT06238284Unknown
HER2 Expression in Gynecological Malignant Tumors in Chongqing Area of China
NCT05979740Phase 2Unknown
RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC
Showing all 3 trials